Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma compa | Eli Lilly is allotting $3 billion to establish an oral medicines ...

Eli Lilly & Co. failed to prove in a federal court that a business selling copycat versions of its obesity drug causes harm ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...